Vaccins contre les hépatites virales : Questions médicales fréquentes
Nom anglais: Viral Hepatitis Vaccines
Descriptor UI:D014761
Tree Number:D20.215.894.899.955
Termes MeSH sélectionnés :
Time-to-Pregnancy
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Vaccins contre les hépatites virales : Questions médicales les plus fréquentes",
"headline": "Vaccins contre les hépatites virales : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Vaccins contre les hépatites virales : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-02-21",
"dateModified": "2025-02-15",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Vaccins contre les hépatites virales"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Vaccins antiviraux",
"url": "https://questionsmedicales.fr/mesh/D014765",
"about": {
"@type": "MedicalCondition",
"name": "Vaccins antiviraux",
"code": {
"@type": "MedicalCode",
"code": "D014765",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D20.215.894.899"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Vaccins anti-hépatite A",
"alternateName": "Hepatitis A Vaccines",
"url": "https://questionsmedicales.fr/mesh/D022362",
"about": {
"@type": "MedicalCondition",
"name": "Vaccins anti-hépatite A",
"code": {
"@type": "MedicalCode",
"code": "D022362",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D20.215.894.899.955.395"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Vaccins anti-hépatite B",
"alternateName": "Hepatitis B Vaccines",
"url": "https://questionsmedicales.fr/mesh/D017325",
"about": {
"@type": "MedicalCondition",
"name": "Vaccins anti-hépatite B",
"code": {
"@type": "MedicalCode",
"code": "D017325",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D20.215.894.899.955.400"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Vaccins contre les hépatites virales",
"alternateName": "Viral Hepatitis Vaccines",
"code": {
"@type": "MedicalCode",
"code": "D014761",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Christoph Neumann-Haefelin",
"url": "https://questionsmedicales.fr/author/Christoph%20Neumann-Haefelin",
"affiliation": {
"@type": "Organization",
"name": "Klinik für Innere Medizin II - Gastroenterologie, Hepatologie, Endokrinologie, Infektiologie, Universitätsklinikum Freiburg, Freiburg, Deutschland."
}
},
{
"@type": "Person",
"name": "Robert Thimme",
"url": "https://questionsmedicales.fr/author/Robert%20Thimme",
"affiliation": {
"@type": "Organization",
"name": "Klinik für Innere Medizin II - Gastroenterologie, Hepatologie, Endokrinologie, Infektiologie, Universitätsklinikum Freiburg, Freiburg, Deutschland. robert.thimme@uniklinik-freiburg.de."
}
},
{
"@type": "Person",
"name": "Maria Buti",
"url": "https://questionsmedicales.fr/author/Maria%20Buti",
"affiliation": {
"@type": "Organization",
"name": "Liver Unit, Hospital Universitario Valle Hebron and Civerehd del Instituto Carlos III, Barcelona, Spain."
}
},
{
"@type": "Person",
"name": "Stefan Zeuzem",
"url": "https://questionsmedicales.fr/author/Stefan%20Zeuzem",
"affiliation": {
"@type": "Organization",
"name": "Department of Internal Medicine 1, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany."
}
},
{
"@type": "Person",
"name": "Fabien Zoulim",
"url": "https://questionsmedicales.fr/author/Fabien%20Zoulim",
"affiliation": {
"@type": "Organization",
"name": "INSERM U1052, CNRS UMR-5286, Cancer Research Center of Lyon, Lyon, France."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Fertility awareness education improves fertility cycle knowledge and may reduce time-to-pregnancy in subfertile women.",
"datePublished": "2023-05-31",
"url": "https://questionsmedicales.fr/article/37254897",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1080/14647273.2023.2214952"
}
},
{
"@type": "ScholarlyArticle",
"name": "Congenital heart disease and the risk of impaired fertility: A Danish nationwide cohort study using time to pregnancy.",
"datePublished": "2023-04-23",
"url": "https://questionsmedicales.fr/article/37094718",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.ijcard.2023.04.021"
}
},
{
"@type": "ScholarlyArticle",
"name": "Variable selection for discrete survival model with frailty in presence of left truncation and right censoring: Studying association of environmental toxicants on time-to-pregnancy.",
"datePublished": "2022-12-01",
"url": "https://questionsmedicales.fr/article/36457137",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/sim.9609"
}
},
{
"@type": "ScholarlyArticle",
"name": "Delayed time to pregnancy and associated factors among pregnant women attending antenatal care in bale zone administrative towns health facilities: multi-center cross-sectional study.",
"datePublished": "2024-08-12",
"url": "https://questionsmedicales.fr/article/39135160",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12884-024-06709-3"
}
},
{
"@type": "ScholarlyArticle",
"name": "Comparison of Time to Pregnancy in",
"datePublished": "2024-09-06",
"url": "https://questionsmedicales.fr/article/39280236",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1155/2024/4139821"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Mélanges complexes",
"item": "https://questionsmedicales.fr/mesh/D045424"
},
{
"@type": "ListItem",
"position": 3,
"name": "Produits biologiques",
"item": "https://questionsmedicales.fr/mesh/D001688"
},
{
"@type": "ListItem",
"position": 4,
"name": "Vaccins",
"item": "https://questionsmedicales.fr/mesh/D014612"
},
{
"@type": "ListItem",
"position": 5,
"name": "Vaccins antiviraux",
"item": "https://questionsmedicales.fr/mesh/D014765"
},
{
"@type": "ListItem",
"position": 6,
"name": "Vaccins contre les hépatites virales",
"item": "https://questionsmedicales.fr/mesh/D014761"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Vaccins contre les hépatites virales - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Vaccins contre les hépatites virales",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-05",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Vaccins contre les hépatites virales",
"description": "Quels sont les symptômes de l'hépatite A ?\nL'hépatite B peut-elle être asymptomatique ?\nComment se manifeste l'hépatite C ?\nQuels signes indiquent une hépatite aiguë ?\nL'hépatite virale peut-elle causer des complications ?",
"url": "https://questionsmedicales.fr/mesh/D014761?mesh_terms=Time-to-Pregnancy&page=2#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Vaccins contre les hépatites virales",
"description": "Comment les vaccins contre l'hépatite A sont-ils administrés ?\nQui devrait recevoir le vaccin contre l'hépatite B ?\nLes vaccins contre l'hépatite A sont-ils efficaces ?\nÀ quel âge doit-on vacciner les enfants contre l'hépatite B ?\nLes voyageurs doivent-ils se faire vacciner contre l'hépatite A ?",
"url": "https://questionsmedicales.fr/mesh/D014761?mesh_terms=Time-to-Pregnancy&page=2#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Vaccins contre les hépatites virales",
"description": "Quel est le traitement de l'hépatite A ?\nComment traite-t-on l'hépatite B chronique ?\nL'hépatite C est-elle curable ?\nQuels médicaments sont utilisés pour l'hépatite B ?\nY a-t-il un vaccin pour l'hépatite C ?",
"url": "https://questionsmedicales.fr/mesh/D014761?mesh_terms=Time-to-Pregnancy&page=2#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Vaccins contre les hépatites virales",
"description": "Quelles sont les complications de l'hépatite B ?\nL'hépatite A peut-elle causer des complications ?\nQuels risques sont associés à l'hépatite C ?\nComment prévenir les complications de l'hépatite ?\nLes complications de l'hépatite peuvent-elles être réversibles ?",
"url": "https://questionsmedicales.fr/mesh/D014761?mesh_terms=Time-to-Pregnancy&page=2#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Vaccins contre les hépatites virales",
"description": "Quels sont les facteurs de risque pour l'hépatite A ?\nQui est à risque d'hépatite B ?\nL'hépatite C est-elle transmissible par le sang ?\nLes travailleurs de la santé sont-ils à risque d'hépatite ?\nLes personnes atteintes de maladies chroniques sont-elles plus à risque ?",
"url": "https://questionsmedicales.fr/mesh/D014761?mesh_terms=Time-to-Pregnancy&page=2#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Quels sont les symptômes de l'hépatite A ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent fatigue, nausées, douleurs abdominales et jaunisse."
}
},
{
"@type": "Question",
"name": "L'hépatite B peut-elle être asymptomatique ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, de nombreuses personnes infectées par l'hépatite B ne présentent pas de symptômes."
}
},
{
"@type": "Question",
"name": "Comment se manifeste l'hépatite C ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes peuvent inclure fatigue, douleurs articulaires et jaunisse, mais souvent absents."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent une hépatite aiguë ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les signes incluent une forte fièvre, des douleurs abdominales et une urine foncée."
}
},
{
"@type": "Question",
"name": "L'hépatite virale peut-elle causer des complications ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des complications comme la cirrhose ou le cancer du foie peuvent survenir."
}
},
{
"@type": "Question",
"name": "Comment les vaccins contre l'hépatite A sont-ils administrés ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils sont généralement administrés par injection intramusculaire en deux doses."
}
},
{
"@type": "Question",
"name": "Qui devrait recevoir le vaccin contre l'hépatite B ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il est recommandé pour tous les nourrissons, les enfants et les adultes à risque."
}
},
{
"@type": "Question",
"name": "Les vaccins contre l'hépatite A sont-ils efficaces ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils offrent une protection d'environ 95% après la vaccination complète."
}
},
{
"@type": "Question",
"name": "À quel âge doit-on vacciner les enfants contre l'hépatite B ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "La vaccination doit commencer à la naissance, avec des doses supplémentaires à 1 et 6 mois."
}
},
{
"@type": "Question",
"name": "Les voyageurs doivent-ils se faire vacciner contre l'hépatite A ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la vaccination est recommandée pour les voyageurs se rendant dans des zones à risque."
}
},
{
"@type": "Question",
"name": "Quel est le traitement de l'hépatite A ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de traitement spécifique ; le repos et l'hydratation sont recommandés."
}
},
{
"@type": "Question",
"name": "Comment traite-t-on l'hépatite B chronique ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des antiviraux peuvent être prescrits pour contrôler l'infection et prévenir les complications."
}
},
{
"@type": "Question",
"name": "L'hépatite C est-elle curable ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des traitements antiviraux modernes peuvent guérir l'hépatite C dans la plupart des cas."
}
},
{
"@type": "Question",
"name": "Quels médicaments sont utilisés pour l'hépatite B ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les médicaments comme le ténofovir et l'entécavir sont couramment utilisés."
}
},
{
"@type": "Question",
"name": "Y a-t-il un vaccin pour l'hépatite C ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, il n'existe pas de vaccin efficace contre l'hépatite C."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications de l'hépatite B ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent la cirrhose, le cancer du foie et l'insuffisance hépatique."
}
},
{
"@type": "Question",
"name": "L'hépatite A peut-elle causer des complications ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Rarement, mais des complications comme l'insuffisance hépatique peuvent survenir chez les personnes âgées."
}
},
{
"@type": "Question",
"name": "Quels risques sont associés à l'hépatite C ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'hépatite C peut entraîner des maladies hépatiques chroniques et des cancers du foie."
}
},
{
"@type": "Question",
"name": "Comment prévenir les complications de l'hépatite ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "La vaccination, le dépistage régulier et un mode de vie sain aident à prévenir les complications."
}
},
{
"@type": "Question",
"name": "Les complications de l'hépatite peuvent-elles être réversibles ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications, comme la fibrose, peuvent être réversibles avec un traitement approprié."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour l'hépatite A ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent le voyage dans des zones à risque et la consommation d'eau contaminée."
}
},
{
"@type": "Question",
"name": "Qui est à risque d'hépatite B ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les personnes ayant des rapports sexuels non protégés et les utilisateurs de drogues injectables sont à risque."
}
},
{
"@type": "Question",
"name": "L'hépatite C est-elle transmissible par le sang ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'hépatite C se transmet principalement par le sang, notamment via les transfusions."
}
},
{
"@type": "Question",
"name": "Les travailleurs de la santé sont-ils à risque d'hépatite ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils sont exposés à un risque accru d'infection par contact avec le sang."
}
},
{
"@type": "Question",
"name": "Les personnes atteintes de maladies chroniques sont-elles plus à risque ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles peuvent avoir un risque accru de complications liées à l'hépatite."
}
}
]
}
]
}
Research suggests that low fertility awareness (FA) may be a contributing factor to infertility. The aim of this study was to determine whether education improves knowledge in FA and to explore the as...
The number of women with congenital heart disease (CHD) becoming pregnant are increasing. Although menstrual irregularities appear to occur more often in these patients, knowledge on their fertility i...
The Danish National Birth Cohort (DNBC) of pregnant women constituted the study population. Information on TTP and use of medically assisted reproduction (MAR) treatment was reported at a first trimes...
Among 93,832 pregnancies in 84,922 women, CHD was diagnosed in 333 women (0.4%), contributing with 360 pregnancies. The CHD was of simple complexity in 291 women (87.4%). No association was found betw...
Women with CHD had no increased risk of impaired fertility, assessed by TTP, when compared with unaffected women. Separate analysis of women with complex CHD was hampered by low numbers....
Understanding the association between mixtures of environmental toxicants and time-to-pregnancy (TTP) is an important scientific question as sufficient evidence has emerged about the impact of individ...
The desire to conceive and become parents is a fundamental aspect of human life that carries immense personal, emotional, and societal significance. For many couples, achieving pregnancy represents a ...
An institutional-based cross-sectional study was conducted from May 1 to May 30, 2023, in public health facilities of Bale Zone administrative towns, Southeast Ethiopia. Using systematic random sampli...
The study revealed delayed time to pregnancy was 18.6% with 95% (CI = 14.67-22.44%). Women's age ≥ 35, (AOR = 2.61; 95%, CI: 1.17-5.82), menstrual irregularity (AOR = 3.79; 95% CI: 1.98-7.25), and fre...
The study revealed a substantial proportion of delayed time to pregnancy. This delayed time to pregnancy was associated with older maternal age, irregular menstrual cycles, coital activity per week, a...
This study is to compare the time to pregnancy (TTP) between patients with endometriosis and nonendometriosis undergoing...
Endometriosis patients had a shorter infertility duration (4 years vs. 5 years,...
Time to pregnancy between endometriosis and nonendometriosis is not significantly different. However, infertility among patients with endometriosis tends to be shorter....
Experimental models have demonstrated a link between exposure to perfluoroalkyl substances (PFAS) and decreased fertility and fecundability; however, human studies are scarce. We assessed the associat...
In a case-control study nested within the population-based Singapore Preconception Study of Long-Term Maternal and Child Outcomes (S-PRESTO), we measured PFAS in plasma collected in 2015-2017 from 382...
We found a 5-10 % reduction in fecundability per quartile increase of exposure to individual PFAS (FRs [95 % CIs] for clinical pregnancy = 0.90 [0.82, 0.98] for PFDA; 0.88 [0.79, 0.99] for PFOS; 0.95 ...
Higher PFAS exposures may be associated with decreased fertility in women. The potential impact of ubiquitous PFAS exposures on infertility mechanisms requires further investigation....
Urinary concentrations of several endocrine disrupting chemicals, including phthalate metabolites, bisphenol A (BPA), and benzophenone (BP)-type ultraviolet (UV) filters, have been associated with a l...
Fecundability (conception rate per menstrual cycle) varies among non-contracepting couples. Time-to-pregnancy studies can identify exposures contributing to that variability, using three designs: inci...
We consider a different generalized linear model, based on an inverse link. It models the heterogeneity as beta distributed and enables estimation of both the FR and FOR, defined based on population m...
The inverse-link approach had slightly less power than the others, but its estimates maintained nominal confidence interval coverage under nonconstancy. A popular method for testing constancy across t...
The inverse-link analysis offers a useful alternative to the usual methods, with estimation performance that generalizes to the ongoing-attempt design and does not require hard-to-verify constancy ass...
To determine the association between ovarian reserve biomarkers and future fertility among late reproductive-age women....
Cohort study of participants enrolled in Time to Conceive (TTC), a time-to-pregnancy cohort study of the ovarian reserve biomarkers....
Community....
Women aged 30-44 years without a history of infertility who provided a blood sample at enrollment in TTC and who agreed to future follow-up....
Not applicable....
The primary outcomes were probability of achieving a live birth >3 years after enrollment in TTC, diagnosis of infertility at any time, and time-to-pregnancy in future pregnancy attempts....
Women with diminished ovarian reserve, defined as those with an antimüllerian hormone (AMH) level <0.7 ng/mL or follicle-stimulating hormone (FSH) level ≥10 mIU/mL, did not have low risk of future liv...
Diminished ovarian reserve is not associated with reduced future reproductive capacity. Given the lack of association, women should be cautioned regarding use biomarkers of ovarian reserve as predicto...
The beginning of the conflict in Ukraine has reminded Europeans the many and diverse consequences of armed conflicts. Indeed, the ever more sophisticated conflicts have led to the diffusion of numerou...